AlphaGenome Atlas, Google DeepMind's new 1-petabyte genomics database, pre-computes predicted molecular effects for all 9 ...

Google DeepMind has released a huge new dataset that could make it easier for scientists to study how changes in our DNA ...

Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why ...

What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation ...

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing ...

Google DeepMind’s 1-petabyte AlphaGenome Atlas predicts the molecular effects of 9 billion possible single-letter changes in human DNA.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative ...

Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Nicole ...

Explore the preclinical research catching our eye in September 2026, from siRNA and in vivo CRISPR to targeted protein ...

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial ...

Google LLC’s DeepMind research unit said today it has used its AlphaGenome artificial intelligence model to predict the ...

The "DNA and Gene Cloning Services - Market Insights, Competitive Landscape, Forecast - 2034" has been added to ResearchAndMarkets.com's offering. The global DNA and gene cloning services market was ...